{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:47:56Z","timestamp":1760147276650,"version":"build-2065373602"},"reference-count":37,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Open Access Publishing Fund of University of T\u00fcbingen"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Primary central nervous system lymphomas (PCNSL) are rare and associated with an adverse prognosis. High-dose chemotherapy followed by autologous stem cell transplantation (HDC\/ASCT) improves progression free (PFS) and overall survival (OS) but neurocognition, performance status and quality of life (QoL) in patient-reported outcome (PRO) after HDC\/ASCT remains underexplored. Especially elderly patients may insufficiently recover from this demanding therapy. Therefore, this single-center analysis investigated all PCNSL patients who received HDC\/ASCT at the University Hospital T\u00fcbingen from 2006\u20132021 (n = 40, median age 60.5 years) in a retrospective manner. The 2-year PFS\/OS was 78.7%\/77.3%, respectively, without significant differences between the tested age-groups (\u226460 vs. &gt;60 years, p = 0.531\/p = 0.334). Higher Thiotepa dosage was an independent predictor for better OS (p = 0.018). Additionally, a one-time prospective, cross-sectional analysis after HDC\/ASCT in the same cohort was performed (n = 31; median follow-up 45 months). Here, the median ECOG improved by HDC\/ASCT from 1 to 0 and mini-mental state examinations revealed unimpaired neurocognitive functioning (median 28 pts.). PRO data collected by EORTC QLQ-C30 showed a good QoL in both age groups with an average global health status (GHS) of 68.82% (\u226460y: 64.72%, &gt;60y: 74.14%). Together, our data indicate that HDC\/ASCT is an effective therapy with respect to disease control, overall health status and quality of life, irrespective of patient age.<\/jats:p>","DOI":"10.3390\/cancers15030669","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T04:19:22Z","timestamp":1674447562000},"page":"669","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient Reported and Clinical Outcomes after High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma"],"prefix":"10.3390","volume":"15","author":[{"given":"Sina A.","family":"Beer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Wirths","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wichard","family":"Vogel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghazaleh","family":"Tabatabai","sequence":"additional","affiliation":[{"name":"Department of Neurology and Interdisciplinary Neuro Oncology, Hertie Institute for Clinial Brain Research, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"},{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen-Stuttgart, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Ernemann","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen-Stuttgart, 72076 T\u00fcbingen, Germany"},{"name":"Department of Neuroradiology, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Merle","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6052-2618","authenticated-orcid":false,"given":"Wolfgang","family":"Bethge","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"M\u00f6hle","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-2805","authenticated-orcid":false,"given":"Claudia","family":"Lengerke","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/ajcp\/110.5.607","article-title":"Primary Central Nervous System Lymphomas in 72 Immunocompetent Patients: Pathologic Findings and Clinical Correlations","volume":"110","author":"Martin","year":"1998","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4103\/0022-3859.58926","article-title":"Primary central nervous system lymphoma: Prognostication as per international extranodal lymphoma study group score and reactive CD3 collar","volume":"55","author":"Kumari","year":"2009","journal-title":"J. Postgrad. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3892\/ijo.2021.5180","article-title":"Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review)","volume":"58","author":"Liu","year":"2021","journal-title":"Int. J. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/bjc.2011.357","article-title":"Age, gender, and racial differences in incidence and survival in primary CNS lymphoma","volume":"105","author":"Villano","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e1027","DOI":"10.1212\/WNL.0000000000008900","article-title":"Management and outcome of primary CNS lymphoma in the modern era: An LOC network study","volume":"94","author":"Houillier","year":"2020","journal-title":"Neurology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000495284","article-title":"Primary CNS Lymphoma in the Elderly: The Challenge","volume":"141","author":"Siegal","year":"2019","journal-title":"Acta Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.18.00306","article-title":"Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study","volume":"37","author":"Houillier","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/annonc\/mdl464","article-title":"Cognitive functions in primary central nervous system lymphoma: Literature review and assessment guidelines","volume":"18","author":"Correa","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1200\/JCO.2003.04.056","article-title":"Primary central nervous system lymphoma: Results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy","volume":"21","author":"Pels","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e3138","DOI":"10.1212\/WNL.0000000000010949","article-title":"Twenty-year follow-up of a pilot\/phase II trial on the Bonn protocol for primary CNS lymphoma","volume":"95","author":"Seidel","year":"2020","journal-title":"Neurology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41409-022-01648-z","article-title":"Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network","volume":"57","author":"Schenone","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","article-title":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","volume":"36","author":"Ferreri","year":"2022","journal-title":"Leukemia"},{"key":"ref_14","first-page":"419","article-title":"The Diagnosis and Treatment of Primary CNS Lymphoma","volume":"115","author":"Illerhaus","year":"2018","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1016\/S1470-2045(18)30356-5","article-title":"Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: A systematic review","volume":"19","author":"Dirven","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/hon.81_2630","article-title":"Bicentric pilot study on age-adapted high-dose chemotherapy and autologous stem cell transplant in newly diagnosed primary cns lymphoma patients > 65 years-marita trial","volume":"37","author":"Schorb","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"20406207211066166","DOI":"10.1177\/20406207211066166","article-title":"Primary central nervous system lymphoma in the United States, 1975\u20132017","volume":"13","author":"Lv","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1182\/blood.V128.22.5385.5385","article-title":"Quality of Life in Patients with Primary CNS Lymphoma-a Pooled Analysis from Three Prospective Multicentre Trials","volume":"128","author":"Kasenda","year":"2016","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1007\/s00277-020-04112-4","article-title":"Factors that predict delayed platelet recovery after autologous stem cell transplantation for lymphoma or myeloma","volume":"99","author":"Nagayama","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbmt.2014.03.001","article-title":"Aging Impairs Long-Term Hematopoietic Regeneration after Autologous Stem Cell Transplantation","volume":"20","author":"Woolthuis","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_23","unstructured":"Fayers, P., Aaronson, N.K., Bjordal, K., Groenvold, M., Curran, D., and Bottomley, A. (2001). The EORTC QLQ-C30 Scoring Manual, European Organisation for Research and Treatment of Cancer. [3rd ed.]. 6f."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Schorb, E., Finke, J., Ihorst, G., Kasenda, B., Fricker, H., and Illerhaus, G. (2019). Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5473-z"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/bmt.2017.23","article-title":"High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: A European retrospective study","volume":"52","author":"Schorb","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","article-title":"Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: Results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0959-8049(00)00447-0","article-title":"Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population","volume":"37","author":"Schwarz","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1212\/01.WNL.0000156350.49336.E2","article-title":"Neuropsychological outcome after chemotherapy for primary CNS lymphoma: A prospective study","volume":"64","author":"Fliessbach","year":"2005","journal-title":"Neurology"},{"key":"ref_30","unstructured":"Weiling, M. (2015). Analyse der Lebensqualit\u00e4t Krebskranker Patienten Mittels EORTC QLQ-30 unter Simultaner Radiochemotherapie. A Quality of Life Analysis Concerning Cancer Patients during Chemoradiotherapy Using the EORTC QLQ-30 2015. [Ph.D. Thesis, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), Medizinische Fakult\u00e4t]."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/jgs.15694","article-title":"Age-Normative MMSE Data for Older Persons Aged 85 to 93 in a Longitudinal Swedish Cohort","volume":"67","author":"Kvitting","year":"2019","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3324\/haematol.2014.113571","article-title":"Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: A prospective multicenter phase II trial","volume":"100","author":"Blaise","year":"2015","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","article-title":"Primary CNS Lymphoma","volume":"35","author":"Grommes","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/cam4.2872","article-title":"A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma","volume":"9","author":"Liu","year":"2020","journal-title":"Cancer Med."},{"key":"ref_35","first-page":"Cd010783","article-title":"Mini-Mental State Examination (MMSE) for the detection of Alzheimer\u2019s disease and other dementias in people with mild cognitive impairment (MCI)","volume":"2015","author":"Smailagic","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1186\/s13063-021-05642-6","article-title":"PRO B: Evaluating the effect of an alarm-based patient-reported outcome monitoring compared with usual care in metastatic breast cancer patients-study protocol for a randomised controlled trial","volume":"22","author":"Karsten","year":"2021","journal-title":"Trials"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Morales-Martinez, A., Lozano-Sanchez, F., Duran-Pe\u00f1a, A., Hoang-Xuan, K., and Houillier, C. (2021). Primary Central Nervous System Lymphoma in Elderly Patients: Management and Perspectives. Cancers, 13.","DOI":"10.3390\/cancers13143479"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/669\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:12:56Z","timestamp":1760119976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,21]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["cancers15030669"],"URL":"https:\/\/doi.org\/10.3390\/cancers15030669","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2023,1,21]]}}}